Stem Cells Archives | Page 87 of 201

denovoMATRIX releases isoMATRIX: Cell and Gene Therapy’s first high-yield MSC isolation technology

December 15, 2021 By Cade Hildreth, Founder & President Leave a Comment

DRESDEN, Germany, December 15, 2021 / BioInformant / — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a new technology for bringing down costs and increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The technology termed isoMATRIX, is designed to isolate MSCs in xeno-/serum-free conditions with high efficiency and stemness enabling rapid cell expansion for radically reduced cost of goods (COGs) for cell therapy manufacturers.

Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings

November 17, 2021 By Cade Hildreth, Founder & President Leave a Comment

Ncardia forms strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services

November 16, 2021, GOSSELIES, Belgium & NEW YORK — Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide. [Read more…]

Shoreline Biosciences Announces $140M Financing To Advance Pipeline of iPSC-based Cell Immunotherapies

November 14, 2021 By Cade Hildreth, Founder & President 1 Comment

Shoreline Biosciences Announces $140M Financing To Advance Its Growing Pipeline Of Next Generation Cell Immunotherapies
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities.

[Read more…]

Curi Bio and NEXEL Form Celogics, a Joint Venture to Develop iPSC-Derived Products

October 27, 2021 By Cade Hildreth, Founder & President Leave a Comment

Celogics, based in Seattle, will offer high-quality iPSC-derived cell products for drug discovery and safety testing.

OCTOBER 26, 2021, SEATTLE and SEOUL – Curi Bio, a global leader in development of human stem cell-based platforms for disease modeling and drug discovery, and NEXEL, a leader in induced pluripotent stem cell (iPSC) technology, today announced the formation of Celogics, a joint venture company focused on the development and commercialization of human iPSC-derived cell products for drug discovery, drug safety testing, and biological research. Celogics iPSC production and distribution headquarters will be located in Seattle, WA. [Read more…]

Bone Therapeutics Signs Research Partnership with Implant Therapeutics to Access iPSCs

October 26, 2021 By Cade Hildreth, Founder & President Leave a Comment

Bone Therapeutics has partnered with Implant Therapeutics to gain access to iPSC derived, genetically engineered MSCs. These
Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines, differentiation protocols and expertise

[Read more…]

Shoreline Biosciences Announces $140M Financing To Advance Its Growing Pipeline Of Next Generation Cell Immunotherapies

Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities.

Celogics, based in Seattle, will offer high-quality iPSC-derived cell products for drug discovery and safety testing.

Bone Therapeutics has partnered with Implant Therapeutics to gain access to iPSC derived, genetically engineered MSCs. These

Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines, differentiation protocols and expertise